# Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19

> **NCT04549922** · PHASE2 · COMPLETED · sponsor: **Hospital do Coracao** · enrollment: 111 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** ISIS 721744
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT04549922
- **Lead sponsor:** Hospital do Coracao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-19
- **Primary completion:** 2020-12-09
- **Final completion:** 2021-12-09
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2022-09-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04549922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04549922, "Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04549922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*